secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-107634
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items
--------------------------------------------------------------------------------

- Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.
- Operating loss improved to $7.0M from $9.3M YoY; cash $12.7M as of June 30.
- Restructuring charges ~$1.5M in Q3 2025; FY2025 guidance being re-evaluated.
- Potential restatement of non-cash OCI/other income related to RIFA and convertible notes; no impact on revenue, gross margin, opex, or cash.
- New strategy: focus on low-dose GLP-1 combo therapy, muscle mass maintenance; FDA PMA accepted for Allurion Balloon; term sheet signed for drug-eluting balloon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025107634/0000950170-25-107634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025107634/alur-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer